Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 218

1.

The Value of Neutrophil to Lymphocyte Ratio in Patients Undergoing Cytoreductive Nephrectomy with Thrombectomy.

Peyton CC, Abel EJ, Chipollini J, Boulware DC, Azizi M, Karam JA, Margulis V, Master VA, Matin SF, Raman JD, Sexton WJ, Wood CG, Spiess PE.

Eur Urol Focus. 2018 Sep 8. pii: S2405-4569(18)30242-6. doi: 10.1016/j.euf.2018.08.023. [Epub ahead of print]

PMID:
30206003
2.

Systematic Review: An Update on the Spectrum of Urological Malignancies in Lynch Syndrome.

Huang D, Matin SF, Lawrentschuk N, Roupret M.

Bladder Cancer. 2018 Jul 30;4(3):261-268. doi: 10.3233/BLC-180180.

3.

Accuracy of High-Frequency Endoluminal Ultrasonography for Clinical Staging of Upper Tract Urothelial Carcinoma.

Farnum JA, Vikram R, Rao A, Bedi D, Dinney CP, Matin SF.

J Endourol. 2018 Sep 12;32(9):806-811. doi: 10.1089/end.2018.0442. Epub 2018 Aug 21.

PMID:
30014707
4.

Conditional survival of patients with small renal masses undergoing active surveillance.

Petros FG, Venkatesan AM, Kaya D, Ng CS, Fellman BM, Karam JA, Wood CG, Matin SF.

BJU Int. 2018 Jul 14. doi: 10.1111/bju.14486. [Epub ahead of print]

PMID:
30007044
5.

Pilot study of dovitinib in patients with von Hippel-Lindau disease.

Pilié P, Hasanov E, Matin SF, Woodson AHH, Marcott VD, Bird S, Slack RS, Fuller GN, McCutcheon IE, Jonasch E.

Oncotarget. 2018 May 4;9(34):23390-23395. doi: 10.18632/oncotarget.25171. eCollection 2018 May 4.

6.

Salvage topical therapy for upper tract urothelial carcinoma.

Balasubramanian A, Metcalfe MJ, Wagenheim G, Xiao L, Papadopoulos J, Navai N, Davis JW, Karam JA, Kamat AM, Wood CG, Dinney CP, Matin SF.

World J Urol. 2018 May 26. doi: 10.1007/s00345-018-2349-9. [Epub ahead of print]

PMID:
29804202
7.

Misclassification of Upper Tract Urothelial Carcinoma in Patients With Lynch Syndrome.

Matin SF, Coleman JA.

JAMA Oncol. 2018 Jul 1;4(7):1010. doi: 10.1001/jamaoncol.2018.0539. No abstract available.

PMID:
29710233
8.

Endoscopic Approaches to Upper Tract Urothelial Carcinoma.

Petros FG, Li R, Matin SF.

Urol Clin North Am. 2018 May;45(2):267-286. doi: 10.1016/j.ucl.2017.12.009. Epub 2018 Feb 21. Review.

PMID:
29650142
9.

Germline genetic variants in somatically significantly mutated genes in tumors are associated with renal cell carcinoma risk and outcome.

Shu X, Gu J, Huang M, Tannir NM, Matin SF, Karam JA, Wood CG, Wu X, Ye Y.

Carcinogenesis. 2018 May 28;39(6):752-757. doi: 10.1093/carcin/bgy021.

PMID:
29635281
10.

Intraoperative Conversion From Partial to Radical Nephrectomy: Incidence, Predictive Factors, and Outcomes.

Petros FG, Keskin SK, Yu KJ, Li R, Metcalfe MJ, Fellman BM, Chang CM, Gu C, Tamboli P, Matin SF, Karam JA, Wood CG.

Urology. 2018 Jun;116:114-119. doi: 10.1016/j.urology.2018.03.017. Epub 2018 Mar 22.

PMID:
29578041
11.

The Adverse Survival Implications of Bland Thrombus in Renal Cell Carcinoma With Venous Tumor Thrombus.

Hutchinson R, Rew C, Chen G, Woldu S, Krabbe LM, Meissner M, Sheth K, Singla N, Shakir N, Master VA, Karam JA, Matin SF, Borregales LD, Wood C, Masterson T, Thompson RH, Boorjian SA, Leibovich BC, Abel EJ, Bagrodia A, Margulis V.

Urology. 2018 May;115:119-124. doi: 10.1016/j.urology.2018.02.019. Epub 2018 Feb 27.

PMID:
29499258
12.

Oncologic outcomes of patients with positive surgical margin after partial nephrectomy: a 25-year single institution experience.

Petros FG, Metcalfe MJ, Yu KJ, Keskin SK, Fellman BM, Chang CM, Gu C, Tamboli P, Matin SF, Karam JA, Wood CG.

World J Urol. 2018 Jul;36(7):1093-1101. doi: 10.1007/s00345-018-2241-7. Epub 2018 Feb 27.

PMID:
29488096
13.

Surgeon-led prostate cancer lymph node staging: pathological outcomes stratified by robot-assisted dissection templates and patient selection.

Altok M, Babaian K, Achim MF, Achim GC, Troncoso P, Matin SF, Chapin BF, Davis JW.

BJU Int. 2018 Jul;122(1):66-75. doi: 10.1111/bju.14164. Epub 2018 Mar 25.

PMID:
29446205
14.

The role of surgery in the management of metastatic kidney cancer: an evidence-based collaborative review.

Mir MC, Matin SF, Bex A, Spiess PE, Thompson RH, Grob B, van Poppel H.

Minerva Urol Nefrol. 2018 Apr;70(2):109-125. doi: 10.23736/S0393-2249.18.03055-2. Epub 2018 Jan 29.

15.

Editorial Comment.

Matin SF.

J Urol. 2018 Apr;199(4):938-939. doi: 10.1016/j.juro.2017.10.064. Epub 2018 Jan 10. No abstract available.

PMID:
29331547
16.

Re: Association Between Lymph Node Yield and Survival Among Patients Undergoing Radical Nephroureterectomy for Urothelial Carcinoma of the Upper Tract.

Petros FG, Matin SF.

Eur Urol. 2018 May;73(5):811-812. doi: 10.1016/j.eururo.2017.12.003. Epub 2017 Dec 14. No abstract available.

PMID:
29249290
17.

Assessment of Ileostomy Output Using Telemedicine: A Feasibility Trial.

Bednarski BK, Slack RS, Katz M, You YN, Papadopolous J, Rodriguez-Bigas MA, Skibber JM, Matin SF, Chang GJ.

Dis Colon Rectum. 2018 Jan;61(1):77-83. doi: 10.1097/DCR.0000000000000945.

PMID:
29215474
18.

Pathologic Predictors of Survival During Lymph Node Dissection for Metastatic Renal-Cell Carcinoma: Results From a Multicenter Collaboration.

Chipollini J, Abel EJ, Peyton CC, Boulware DC, Karam JA, Margulis V, Master VA, Zargar-Shoshtari K, Matin SF, Sexton WJ, Raman JD, Wood CG, Spiess PE.

Clin Genitourin Cancer. 2018 Apr;16(2):e443-e450. doi: 10.1016/j.clgc.2017.10.004. Epub 2017 Oct 17.

PMID:
29113770
19.

Glycemic index, glycemic load and carbohydrate intake in association with risk of renal cell carcinoma.

Zhu J, Tu H, Matin SF, Tannir NM, Wood CG, Wu X.

Carcinogenesis. 2017 Oct 26;38(11):1129-1135. doi: 10.1093/carcin/bgx083.

PMID:
28968893
20.

A decade of robot-assisted radical prostatectomy training: Time-based metrics and qualitative grading for fellows and residents.

Altok M, Achim MF, Matin SF, Pettaway CA, Chapin BF, Davis JW.

Urol Oncol. 2018 Jan;36(1):13.e19-13.e25. doi: 10.1016/j.urolonc.2017.08.028. Epub 2017 Sep 28.

PMID:
28964658
21.

Local Tumor Bed Recurrence Following Partial Nephrectomy in Patients with Small Renal Masses.

Wood EL, Adibi M, Qiao W, Brandt J, Zhang M, Tamboli P, Matin SF, Wood CG, Karam JA.

J Urol. 2018 Feb;199(2):393-400. doi: 10.1016/j.juro.2017.09.072. Epub 2017 Sep 20.

PMID:
28941919
22.

Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohort.

Blanchard P, Davis JW, Frank SJ, Kim J, Pettaway CA, Pugh TJ, Pisters LL, Ward JF, Choi S, Chapin BF, Hoffman K, Navai N, Achim M, McGuire SE, Matin SF, Nguyen Q, Mahmood U, Graber WJ, Chen HC, Wang X, Kuban DA.

BJU Int. 2018 Apr;121(4):540-548. doi: 10.1111/bju.14021. Epub 2017 Oct 17.

PMID:
28941030
23.

HNF1B Loss Exacerbates the Development of Chromophobe Renal Cell Carcinomas.

Sun M, Tong P, Kong W, Dong B, Huang Y, Park IY, Zhou L, Liu XD, Ding Z, Zhang X, Bai S, German P, Powell R, Wang Q, Tong X, Tannir NM, Matin SF, Rathmell WK, Fuller GN, McCutcheon IE, Walker CL, Wang J, Jonasch E.

Cancer Res. 2017 Oct 1;77(19):5313-5326. doi: 10.1158/0008-5472.CAN-17-0986. Epub 2017 Aug 14.

PMID:
28807937
24.

Universal Point of Care Testing for Lynch Syndrome in Patients with Upper Tract Urothelial Carcinoma.

Metcalfe MJ, Petros FG, Rao P, Mork ME, Xiao L, Broaddus RR, Matin SF.

J Urol. 2018 Jan;199(1):60-65. doi: 10.1016/j.juro.2017.08.002. Epub 2017 Aug 7.

PMID:
28797715
25.

Induction and Maintenance Adjuvant Mitomycin C Topical Therapy for Upper Tract Urothelial Carcinoma: Tolerability and Intermediate Term Outcomes.

Metcalfe M, Wagenheim G, Xiao L, Papadopoulos J, Navai N, Davis JW, Karam JA, Kamat AM, Wood CG, Dinney CP, Matin SF.

J Endourol. 2017 Sep;31(9):946-953. doi: 10.1089/end.2016.0871. Epub 2017 Jul 21.

26.

Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma.

Moss TJ, Qi Y, Xi L, Peng B, Kim TB, Ezzedine NE, Mosqueda ME, Guo CC, Czerniak BA, Ittmann M, Wheeler DA, Lerner SP, Matin SF.

Eur Urol. 2017 Oct;72(4):641-649. doi: 10.1016/j.eururo.2017.05.048. Epub 2017 Jun 7.

PMID:
28601352
27.

Optimizing management of upper tract urothelial carcinoma.

Campbell MT, Shah AY, Matin SF, Siefker-Radtke AO.

Urol Oncol. 2017 Jul;35(7):492-498. doi: 10.1016/j.urolonc.2017.05.009. Epub 2017 Jun 1. Review.

PMID:
28579283
28.

Editorial Comment.

Matin SF.

J Urol. 2017 Sep;198(3):551. doi: 10.1016/j.juro.2017.03.148. Epub 2017 May 24. No abstract available.

PMID:
28551454
29.

Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy Eras.

Keskin SK, Msaouel P, Hess KR, Yu KJ, Matin SF, Sircar K, Tamboli P, Jonasch E, Wood CG, Karam JA, Tannir NM.

J Urol. 2017 Sep;198(3):530-537. doi: 10.1016/j.juro.2017.04.067. Epub 2017 Apr 11.

30.

Cytoreductive Nephrectomy for Renal Cell Carcinoma with Venous Tumor Thrombus.

Abel EJ, Spiess PE, Margulis V, Master VA, Mann M, Zargar-Shoshtari K, Borregales LD, Sexton WJ, Patil D, Matin SF, Wood CG, Karam JA.

J Urol. 2017 Aug;198(2):281-288. doi: 10.1016/j.juro.2017.03.011. Epub 2017 Mar 6.

PMID:
28268170
31.

Re: Targeting Renal Cell Carcinoma with a HIF-2 Antagonist.

Ferguson JE 3rd, Matin SF.

Eur Urol. 2017 Jun;71(6):987. doi: 10.1016/j.eururo.2017.02.015. Epub 2017 Feb 23. No abstract available.

PMID:
28237787
32.

Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy Era.

Kalra S, Verma J, Atkinson BJ, Matin SF, Wood CG, Karam JA, Lin SH, Satcher RL, Tamboli P, Sircar K, Rao P, Corn PG, Tannir NM, Jonasch E.

Clin Genitourin Cancer. 2017 Jun;15(3):363-370. doi: 10.1016/j.clgc.2017.01.010. Epub 2017 Jan 18.

PMID:
28216278
33.

Robot assisted lymphadenectomy in urology: pelvic, retroperitoneal and inguinal.

Pini G, Matin SF, Suardi N, Desai M, Gill I, Porter J, Stein RJ, Sotelo R, Gaboardi F, Porpiglia F.

Minerva Urol Nefrol. 2017 Feb;69(1):38-55. doi: 10.23736/S0393-2249.16.02823-X. Epub 2016 Nov 8. Review.

PMID:
28009144
34.

Editorial Comment.

Metcalfe MJ, Matin SF.

Urology. 2017 Feb;100:150. doi: 10.1016/j.urology.2016.07.064. Epub 2016 Dec 16. No abstract available.

PMID:
27993389
35.

MicroRNA profiling in clear cell renal cell carcinoma tissues potentially links tumorigenesis and recurrence with obesity.

Shu X, Hildebrandt MA, Gu J, Tannir NM, Matin SF, Karam JA, Wood CG, Wu X.

Br J Cancer. 2017 Jan 3;116(1):77-84. doi: 10.1038/bjc.2016.392. Epub 2016 Dec 1.

36.

Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study.

Shah AY, Karam JA, Malouf GG, Rao P, Lim ZD, Jonasch E, Xiao L, Gao J, Vaishampayan UN, Heng DY, Plimack ER, Guancial EA, Fung C, Lowas SR, Tamboli P, Sircar K, Matin SF, Kimryn Rathmell W, Wood CG, Tannir NM.

BJU Int. 2017 Dec;120(6):782-792. doi: 10.1111/bju.13705. Epub 2016 Dec 9.

PMID:
27860149
37.

Upper Urinary Tract Carcinoma In Situ: Current Knowledge, Future Direction.

Redrow GP, Guo CC, Brausi MA, Coleman JA, Fernandez MI, Kassouf W, Keeley FX Jr, Margulis V, Raman JD, Roupret M, Shariat SF, Spiess PE, Thalmann GN, Matin SF.

J Urol. 2017 Feb;197(2):287-295. doi: 10.1016/j.juro.2016.03.194. Epub 2016 Sep 21. Review.

PMID:
27664578
38.

Cryoablation for cT1b Renal Tumors? Yet To Be Determined.

Petros FG, Matin SF.

Eur Urol. 2017 Jan;71(1):118-119. doi: 10.1016/j.eururo.2016.09.004. Epub 2016 Sep 9. No abstract available.

PMID:
27616722
39.

Kidney cancer: Quality-of-life outcomes in patients with small renal masses.

Matin SF.

Nat Rev Urol. 2016 Aug;13(8):443-4. doi: 10.1038/nrurol.2016.124. Epub 2016 Jul 12. Review. No abstract available.

PMID:
27400666
40.

Author reply.

Matin SF, Melquist J, Karam JA.

Urology. 2016 Jan;87:222-3. No abstract available.

PMID:
27243090
41.

Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of low-risk upper tract urothelial carcinoma.

Mandalapu RS, Remzi M, de Reijke TM, Margulis V, Palou J, Kapoor A, Yossepowitch O, Coleman J, Traxer O, Anderson JK, Catto J, de la Rosette J, O'Brien T, Zlotta A, Matin SF.

World J Urol. 2017 Mar;35(3):355-365. doi: 10.1007/s00345-016-1859-6. Epub 2016 May 27. Review.

42.

Examination of moderators of expressive writing in patients with renal cell carcinoma: the role of depression and social support.

Milbury K, Lopez G, Spelman A, Wood C, Matin SF, Tannir NM, Jonasch E, Pisters L, Wei Q, Cohen L.

Psychooncology. 2017 Sep;26(9):1361-1368. doi: 10.1002/pon.4148. Epub 2016 May 3.

43.

Predicting and Determining the Success of Percutaneous Ablation.

Sabir S, Ahrar K, Matin SF.

J Urol. 2016 Jul;196(1):7-8. doi: 10.1016/j.juro.2016.04.043. Epub 2016 Apr 13. No abstract available.

PMID:
27086180
44.

Outpatient virtual clinical encounters after complex surgery for cancer: a prospective pilot study of "TeleDischarge".

Katz MH, Slack R, Bruno M, McMillan J, Fleming JB, Lee JE, Bednarski B, Papadopoulos J, Matin SF.

J Surg Res. 2016 May 1;202(1):196-203. doi: 10.1016/j.jss.2015.12.054. Epub 2016 Jan 6.

PMID:
27083967
45.

Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of localized high-risk disease.

Gakis G, Schubert T, Alemozaffar M, Bellmunt J, Bochner BH, Boorjian SA, Daneshmand S, Huang WC, Kondo T, Konety BR, Laguna MP, Matin SF, Siefker-Radtke AO, Shariat SF, Stenzl A.

World J Urol. 2017 Mar;35(3):327-335. doi: 10.1007/s00345-016-1819-1. Epub 2016 Apr 4. Review.

PMID:
27043218
46.

The Role of Metastasectomy in Patients with Renal Cell Carcinoma with Sarcomatoid Dedifferentiation: A Matched Controlled Analysis.

Thomas AZ, Adibi M, Slack RS, Borregales LD, Merrill MM, Tamboli P, Sircar K, Jonasch E, Tannir NM, Matin SF, Wood CG, Karam JA.

J Urol. 2016 Sep;196(3):678-84. doi: 10.1016/j.juro.2016.03.144. Epub 2016 Mar 29.

47.

Upper tract urothelial carcinoma: epidemiology, high risk populations and detection.

Redrow GP, Matin SF.

Minerva Urol Nefrol. 2016 Aug;68(4):350-8. Epub 2016 Mar 23.

PMID:
27008468
48.

Contemporary Evaluation and Management of Upper Tract Urothelial Cancer.

Mandalapu RS, Matin SF.

Urology. 2016 Aug;94:17-23. doi: 10.1016/j.urology.2015.12.035. Epub 2016 Feb 2. Review.

PMID:
26850816
49.

Prognosticators and outcomes of patients with renal cell carcinoma and adjacent organ invasion treated with radical nephrectomy.

Borregales LD, Kim DY, Staller AL, Qiao W, Thomas AZ, Adibi M, Tamboli P, Sircar K, Jonasch E, Tannir NM, Matin SF, Wood CG, Karam JA.

Urol Oncol. 2016 May;34(5):237.e19-26. doi: 10.1016/j.urolonc.2015.11.020. Epub 2015 Dec 18.

50.

Genomic DNA Hypomethylation and Risk of Renal Cell Carcinoma: A Case-Control Study.

Mendoza-Pérez J, Gu J, Herrera LA, Tannir NM, Matin SF, Karam JA, Huang M, Chang DW, Wood CG, Wu X.

Clin Cancer Res. 2016 Apr 15;22(8):2074-82. doi: 10.1158/1078-0432.CCR-15-0977. Epub 2015 Dec 11.

Supplemental Content

Loading ...
Support Center